A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)

Catherine Sebban (1) , Anne Lefranc (2) , Lionel Perrier (2, 3) , Philippe Moreau (4) , Daniel Espinouse (5) , A. Schmidt (2) , L. Kammoun (2) , Hervé Ghesquières (6) , C. Ferlay (2) , Jacques-Olivier Bay (7) , Séverine Lissandre (8) , David Pérol (9) , M. Michallet (2) , Philippe Quittet (10)

1 Department of Medical Oncology
2 Centre Léon Bérard [Lyon]
3 GATE Lyon Saint-Étienne - Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne
4 Hématologie et oncologie pédiatrique
5 Hématologie clinique
6 FNCLCC - Département Hématologie
7 Unité de transplantation médullaire et laboratoire d'oncologie moléculaire
8 Service d'hématologie [Tours]
9 Department of Biostatistics
10 Service d'hématologie et oncologie médicale

Mots clés: pegfilgrastim; filgrastim; myeloma; lymphoma; cost-effectiveness; stem cell; palm; transplant; stem; randomis phase; autologou stem; after autologou; randomis; cell transplant

Domaines: Economies et finances

Catherine Sebban, Anne Lefranc, Lionel Perrier, Philippe Moreau, Daniel Espinouse, et al.. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). European Journal of Cancer, 2012, 48 (5), pp. 713-720. ⟨halshs-00680996⟩